Irini Chatziralli1, Eleni Dimitriou2, George Theodossiadis2, Evgenia Bourouki2, Eleni Bagli3, George Kitsos3, Panagiotis Theodossiadis2. 1. 2nd Department of Ophthalmology, Attikon Hospital, National and Kapodistrian University of Athens, 1, Rimini street, 12462, Haidari, Greece. eirchat@yahoo.gr. 2. 2nd Department of Ophthalmology, Attikon Hospital, National and Kapodistrian University of Athens, 1, Rimini street, 12462, Haidari, Greece. 3. Department of Ophthalmology, University of Ioannina, Ioannina, Greece.
Abstract
PURPOSE: To compare prospectively intravitreal ranibizumab treatment and pars plana vitrectomy (PPV) in patients with recurrent vitreous haemorrhage (VH) due to proliferative diabetic retinopathy (PDR), who were previously treated with PPV. METHODS: Participants in this prospective study were 37 patients (37 eyes) with PDR, previously treated with PPV. All patients presented recurrent VH and were treated with either ranibizumab (n = 18) or PPV (n = 19). All participants were examined at week 2 post-treatment and every month thereafter for 1 year. Main outcomes were the need of PPV, the rate of recurrence of VH and the change in visual acuity by the end of the 12-month follow-up. RESULTS: At month 12, there was statistically significant improvement in visual acuity in both groups compared to baseline, but the two groups did not differ regarding the change in visual acuity. In ranibizumab group, two patients presented recurrent VH during the follow-up and one patient needed PPV to clear the VH by month 12. In PPV group, two patients had mild recurrent VH, which cleared itself. No statistically significant difference was noticed regarding the rate of recurrent VH and the need of PPV between the two groups. CONCLUSION: Intravitreal ranibizumab seems to be a safe and effective treatment alternative in patients with recurrent VH secondary to PDR, who had been previously treated with PPV.
PURPOSE: To compare prospectively intravitreal ranibizumab treatment and pars plana vitrectomy (PPV) in patients with recurrent vitreous haemorrhage (VH) due to proliferative diabetic retinopathy (PDR), who were previously treated with PPV. METHODS:Participants in this prospective study were 37 patients (37 eyes) with PDR, previously treated with PPV. All patients presented recurrent VH and were treated with either ranibizumab (n = 18) or PPV (n = 19). All participants were examined at week 2 post-treatment and every month thereafter for 1 year. Main outcomes were the need of PPV, the rate of recurrence of VH and the change in visual acuity by the end of the 12-month follow-up. RESULTS: At month 12, there was statistically significant improvement in visual acuity in both groups compared to baseline, but the two groups did not differ regarding the change in visual acuity. In ranibizumab group, two patients presented recurrent VH during the follow-up and one patient needed PPV to clear the VH by month 12. In PPV group, two patients had mild recurrent VH, which cleared itself. No statistically significant difference was noticed regarding the rate of recurrent VH and the need of PPV between the two groups. CONCLUSION: Intravitreal ranibizumab seems to be a safe and effective treatment alternative in patients with recurrent VH secondary to PDR, who had been previously treated with PPV.
Authors: Jeffrey G Gross; Adam R Glassman; Lee M Jampol; Seidu Inusah; Lloyd Paul Aiello; Andrew N Antoszyk; Carl W Baker; Brian B Berger; Neil M Bressler; David Browning; Michael J Elman; Frederick L Ferris; Scott M Friedman; Dennis M Marcus; Michele Melia; Cynthia R Stockdale; Jennifer K Sun; Roy W Beck Journal: JAMA Date: 2015-11-24 Impact factor: 56.272
Authors: M R Moreno; T S Tabitha; J Nirmal; K Radhakrishnan; C H Yee; S Lim; S Venkatraman; R Agrawal Journal: Eur J Pharm Biopharm Date: 2016-09-08 Impact factor: 5.571
Authors: Vrinda S Hershberger; James J Augsburger; Robert K Hutchins; Lawrence A Raymond; Stewart Krug Journal: Ophthalmology Date: 2004-06 Impact factor: 12.079